Wall Street analyst estimates for Lisata Therapeutics, Inc. (LSTA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues.
Valuation Ratios
| Price / Book | 0.97 |
| EV / EBITDA | -0.01 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.0M | $170000 |
| Cost of Revenue | $450266 | $372000 | $225000 | $65000 | $63000 | 0 | 0 | 0 | 0 | $146000 |
| Gross Profit | $4.1M | -$372000 | -$225000 | -$65000 | -$63000 | 0 | 0 | 0 | $1.0M | $24000 |
| Research & Development | $15.1M | $17.1M | $7.6M | $13.5M | $9.3M | $17.6M | $43.5M | $12.7M | $11.3M | $7.9M |
| Selling, General & Admin | $12.8M | $11.8M | $9.4M | $9.3M | $9.9M | $11.5M | $14.1M | $13.0M | $12.1M | $10.4M |
| Operating Expenses | $35.5M | $27.6M | $17.0M | $20.1M | $19.1M | $29.1M | $57.6M | $25.7M | $23.4M | $18.2M |
| Operating Income | -$31.3M | -$27.6M | -$17.0M | -$20.1M | -$19.1M | -$29.1M | -$57.6M | -$25.7M | -$22.4M | -$18.2M |
| EBITDA | -$29.0M | -$27.2M | -$16.8M | -$20.0M | -$19.1M | -$28.9M | -$56.6M | -$23.0M | -$20.6M | -$17.4M |
| Interest Expense | $1.9M | $377768 | $5000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$31.3M | -$27.7M | -$16.2M | -$19.4M | -$19.0M | -$29.0M | -$56.7M | -$23.2M | -$20.8M | -$17.5M |
| Income Tax | $138038 | -$11.5M | -$1000 | 0 | -$10.9M | -$1.5M | -$2.5M | -$2.3M | -$798000 | -$962000 |
| Net Income | -$32.7M | $23.0M | -$16.2M | -$20.1M | -$8.2M | -$27.5M | -$54.2M | -$20.8M | -$20.0M | -$16.6M |
| EPS | $-74.81 | $38.43 | $-25.03 | $-29.20 | $-7.91 | $-7.45 | $-10.47 | $-2.58 | $-2.40 | $-1.91 |
| EPS (Diluted) | $-74.81 | $38.43 | $-25.03 | $-29.20 | $-7.91 | $-7.45 | $-10.47 | $-2.58 | $-2.40 | $-1.91 |
| Shares Outstanding (Diluted) | $436550 | $597933 | $645933 | $688333 | $1.0M | $3.7M | $5.2M | $8.1M | $8.3M | $8.7M |
Price
| Price | $1.47 |
| Market Cap | $13M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CASI · CLGN · CLSD · ENLV · KLTO · MTVA · NCNA
Explore sector: Healthcare · Biotechnology
More sections of LSTA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks